Clinical Development Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Clinical Development stocks.

Clinical Development Stocks Recent News

Date Stock Title
May 15 LDOS 5 Dividend Stocks to Boost Portfolio Growth
May 15 DCTH Delcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...
May 14 DCTH Delcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript
May 14 REGN Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
May 14 REGN Evercore says biotech ‘winter is finally thawing’
May 14 LDOS Leidos (LDOS) Wins $631M Deal to Aid US Army's DIABLO Program
May 14 NBIX Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
May 14 LDOS Leidos and Elroy Air to demonstrate autonomous aerial resupply drone for U.S. Marine Corps
May 14 DCTH Delcath Systems GAAP EPS of -$0.45 beats by $0.02, revenue of $3.14M beats by $0.95M
May 14 DCTH Delcath Systems Reports First Quarter 2024 Results and Business Highlights
May 13 DCTH Delcath Systems Q1 2024 Earnings Preview
May 13 REGN Dupixent set for FDA review in adolescent chronic inflammatory sinus disease
May 13 REGN Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
May 13 GMED Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
May 13 LDOS Zacks.com featured highlights Hasbro, Brinker International, DaVita, Leidos Holdings and Allstate
May 13 REGN Pipeline Moves: Phase III completion for Corcept’s relaorilant
May 13 REGN Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
May 10 MACK Merrimack Pharmaceuticals stockholders approve plan of dissolution
May 10 NKTR Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript
May 10 MACK Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
Clinical Development

Clinical development is the process of developing a new drug, medical device, or diagnostic test from the initial concept to the point of regulatory approval. It involves a series of steps, including preclinical research, clinical trials, regulatory review, and post-marketing surveillance. The goal of clinical development is to demonstrate the safety and efficacy of a product in order to obtain regulatory approval for marketing.

Browse All Tags